mianserin has been researched along with Stroke in 4 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with ischemic stroke received either 30 mg mirtazapine or no antidepressant medication from day 1 after the stroke in an open, randomized study design." | 9.11 | Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. ( Bohrer, E; Heuser, I; Niedermaier, N; Schlattmann, P; Schulte, K, 2004) |
| "We assessed the prevalence and associations of symptoms of insomnia in patients with acute ischemic stroke, and evaluated whether mianserin as a sedative antidepressant is beneficial in the treatment of poststroke insomnia." | 9.10 | Complaints of poststroke insomnia and its treatment with mianserin. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Meririnne, E; Palomäki, H, 2003) |
| "Mirtazapine may be a probably effective treatment in stroke survivors with obstructive sleep apnea who refuse nasal CPAP treatment." | 6.73 | Success and failure of mirtazapine as alternative treatment in elderly stroke patients with sleep apnea-a preliminary open trial. ( Brunner, H, 2008) |
| "Patients with ischemic stroke received either 30 mg mirtazapine or no antidepressant medication from day 1 after the stroke in an open, randomized study design." | 5.11 | Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. ( Bohrer, E; Heuser, I; Niedermaier, N; Schlattmann, P; Schulte, K, 2004) |
| "We assessed the prevalence and associations of symptoms of insomnia in patients with acute ischemic stroke, and evaluated whether mianserin as a sedative antidepressant is beneficial in the treatment of poststroke insomnia." | 5.10 | Complaints of poststroke insomnia and its treatment with mianserin. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Meririnne, E; Palomäki, H, 2003) |
| "Mirtazapine may be a probably effective treatment in stroke survivors with obstructive sleep apnea who refuse nasal CPAP treatment." | 2.73 | Success and failure of mirtazapine as alternative treatment in elderly stroke patients with sleep apnea-a preliminary open trial. ( Brunner, H, 2008) |
| "Depression is associated with stroke severity and functional impairment, and with the male sex at 18 months." | 2.71 | Poststroke depression: an 18-month follow-up. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Palomäki, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palomäki, H | 2 |
| Berg, A | 2 |
| Meririnne, E | 1 |
| Kaste, M | 2 |
| Lönnqvist, R | 1 |
| Lehtihalmes, M | 2 |
| Lönnqvist, J | 2 |
| Niedermaier, N | 1 |
| Bohrer, E | 1 |
| Schulte, K | 1 |
| Schlattmann, P | 1 |
| Heuser, I | 1 |
| Brunner, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for mianserin and Stroke
| Article | Year |
|---|---|
Complaints of poststroke insomnia and its treatment with mianserin.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, | 2003 |
Poststroke depression: an 18-month follow-up.
Topics: Antidepressive Agents, Second-Generation; Depression; Female; Follow-Up Studies; Humans; Male; Mians | 2003 |
Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke.
Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration Schedule; Female; F | 2004 |
Success and failure of mirtazapine as alternative treatment in elderly stroke patients with sleep apnea-a preliminary open trial.
Topics: Adrenergic alpha-Antagonists; Aged; Body Mass Index; Continuous Positive Airway Pressure; Electromyo | 2008 |